Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: A 6-month pilot scale trial in Canada

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1919-1930

  Ranganathan, Natarajan ^a   Friedman, Eli A ^b   Tam, Paul ^c   Rao, Venkat ^d   Ranganathan, Parimalam ^a   Dheer, Rahul ^a  

^a Newtown Business Center   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c SCARBOROUGH HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Disease progression; Healthy kidney; Probiotics; Uremic syndrome

Indexed keywords

C REACTIVE PROTEIN; CREATININE; PLACEBO; PROBIOTIC AGENT; URIC ACID;

ADULT; AGED; ARTICLE; CANADA; CHEMICAL PARAMETERS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; INFECTIOUS COMPLICATION; INTESTINE FLORA; KIDNEY FUNCTION; MALE; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCREENING; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; WELLBEING;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ONTARIO; OUTCOME ASSESSMENT (HEALTH CARE); PILOT PROJECTS; PROBIOTICS; PROSPECTIVE STUDIES;

EID: 67650812006     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903069249     Document Type: Article

References (34)

1. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis 2001;32:1567-76
2. Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther 2006;4:261-75
3. Gill HS, Guarner F. Probiotics and human health: a clinical perspective. Postgrad Med J 2004;80:516-26
4. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am 2006;35:355-65
5. Ezendam J, van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev 2006;64:1-14
6. Ranganathan N, Patel B, Ranganathan P, et al. Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. The Scientific World Journal 2005;5:652-60
7. Ranganathan N, Patel BG, Ranganathan P, et al. In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J 2006;52:70-9
8. Ranganathan N, Friedman EA. Progress in devising a bowel based probiotic therapy for uremia. Poster Presentation, BIO International Convention, 2007, Boston, MA
9. Dunn SR, Marczely J, Ranganathan P, et al. Probiotics extend survival in untreated 5/6 nephrectomized rats: possible use for probiotics as an adjunct in chronic renal failure (CRF). Poster Presentation, J Am Soc Nephrol 2003;14
10. Patel B, Zelenaia O, Dheer R, et al. Oral bacteriotherapy effectively reduces severity of azotemia in 5/6th nephrectomized rats. Poster Presentation, J Am Soc Nephrol, 2003;14
11. Willis L, Handa R, Paterson R, et al. Oral probiotic treatment for uremia in a porcine model of chronic renal failure. Poster Presentation, J Am Soc Nephrol, 2004;15
12. Patel B, Marczely J, Ranganathan N, et al. Gut based uremia therapy: oral bacteriotherapy effectively reduces severity of azotemia in 5/6th nephrectomized mini pigs. Poster Presentation, International Society of Nephrology Conference on Prevention of Progression of Renal Disease, 2004
13. Ranganathan N, Patel B, Ranganathan P, et al. Probiotics reduce azotemia in Gottingen minipigs. Poster Presentation, 3rd World Congress of Nephrology, 2005
14. Friedman EA, Macherone A, Ranganathan N, et al. Gut based uremia therapy: simultaneously eliminate urea, creatinine and uric acid. J Am Soc Nephrol, 2001;12:71-2A
15. Patel B, Macherone A, Marczely J, et al. Viability of probiotics in gastric juice and artificial intestinal fluid. J Am Soc Nephrol, 2002;13:767A
16. Ranganathan N, Macherone A, Patel B, et al. Urea hydrolysis and ammonia uptake by Bacillus pasteurii. Poster Presentation, 10th International Congress on Nutrition and Metabolism in Renal Disease, 2002
17. Ranganathan N, Macherone A, Patel B, et al. Probiotics to eliminate nitrogenous metabolites. Poster Presentation, 10th International Congress on Nutrition and Metabolism in Renal Disease, 2002
18. Ranganathan N, Macherone A, Patel B, et al. Probiotics to eliminate nitrogenous metabolites. Poster Presentation, 10th International Congress on Nutrition and Metabolism in Renal Disease, 2002
19. Marczely J, Dheer R, Zelenaia O, et al. Rate of urea hydrolysis by Streptococcus thermophilus KB19 is comparable to soil bacterium Bacillus pasteurii and genetically engineered urealytic E. coli. Poster Presentation, J Am Soc Nephrol, 2003;14
20. Zelenaia O, Patel G, Dheer R, et al. Streptococcus thermophilus KB19 is a potential component of a probiotic regimen applicable in enteric dialysis for uremia. Poster Presentation, J Am Soc Nephrol, 2003;14
21. Patel B, Ranganathan N, Friedman EA. Artificial swallowable kidney formulation. Poster Presentation, American Society of Artificial and Internal Organs - International Society of Artificial and Internal Organs Joint Conference, 2003
22. Patel B, Ranganathan N, Zelenaia O, et al. Substitution of the kidney function by the bowel in azotemia. Poster Presentation, J Am Soc Nephrol, 2004; 15
23. Dheer R, Chordia T, Pechenyak B, et al. Kibow Biotics is preferred and superior to yogurt for uremia applications. Poster Presentation, J Am Soc Nephrol, 2004; 15
24. Marczely J, Dheer R, Ranganathan P, et al. Probiotic formulation in vitro effect on phenol and p-cresol levels. Poster Presentation, J Am Soc Nephrol, 2004
25. Patel B, Dheer R, Pechenyak B, Marczely J, et al. Mode of delivery and dosage are important factors for uremia therapy with probiotics. Poster Presentation J Am Soc Nephrol, 2004
26. Chordia T, Dheer R, Pechenyak, et al. Significance of dosage for effective clinical application of probiotics. Poster Presentation, J Am Soc Nephrol, 2004
27. Patel B, Marczely J, Ranganathan P, et al. Gut based uremia therapy: continued in vitro and in vivo R&D investigations on the application of oral probiotic bacteriotherapy towards chronic kidney disease (CKD) patients. 12th International Congress on Nutrition and Metabolism in Renal Disease - Free Communication FC-A8
28. Patel B, Zelenaia O, Dheer R, et al. Gut-based uremia therapy: in vitro R&D investigations of an oral probiotic microbial formulation with the aid of a simulated human intestinal microbial ecosystem (SHIME) biochemical reactor. Poster Presentation, International Society of Nephrology Conference on Prevention of Progression of Renal Disease, 2004
29. Patel B, Dheer R, Marczely J, et al. Comparative microbial viability analysis in two delivery formats - gelcaps or admixed with food/diet. Poster Presentation, 12th International Congress on Nutrition and Metabolism in Renal Disease, 2004
30. Patel B, Dheer R, Marczely J, et al. Short term effect of temperature on Kibow Biotics Poster Presentation, 3rd World Congress of Nephrology, Singapore, 2005
31. Ranganathan P, Marczely J, Dheer J, et al. Initial trial of probiotic bacteria as therapy for uremia in dogs. Poster Presentation, J Am Soc Nephrol, 2004
32. Ranganathan N, Patel G, Ranganathan P, et al. Effect of feeding Kibow Biotics to cats and dogs in kidney failure. Poster Presentation, 39th Annual Meeting of American Society of Nephrology, 2006
33. Ranganathan N, Patel G, Ranganathan P, et al. Progress in devising a bowel based probiotic therapy for uremia. 5th Annual Meeting on Prevention in Renal Disease, 2006, Toronto, Canada
34. Palmquist R. A preliminary clinical evaluation of Kibow Biotics®, a probiotic agent, on feline azotemia. J Am Holistic Vet Med Assoc, 2006;24:23-7